---
title: "Analyst Maintains Buy on Encompass Health as Model Tweaks Leave 2026 Revenue and EBITDA Outlook Intact"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293075718.md"
description: "William Blair analyst Jared Haase maintained a Buy rating on Encompass Health (EHC) on July 9, citing stable fundamentals and aligned expectations. His updated model keeps the 2026 revenue and EBITDA outlook intact, with minor tweaks to near-term assumptions like Q2 discharge growth. Barclays also maintained a Buy rating with a $140 price target on the same day."
datetime: "2026-07-17T21:15:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293075718.md)
  - [en](https://longbridge.com/en/news/293075718.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293075718.md)
---

# Analyst Maintains Buy on Encompass Health as Model Tweaks Leave 2026 Revenue and EBITDA Outlook Intact

William Blair analyst Jared Haase has maintained their bullish stance on EHC stock, giving a Buy rating on July 9.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Jared Haase has given his Buy rating due to a combination of factors that reflect stable fundamentals and aligned expectations with guidance. His updated model still projects 2026 revenue modestly above consensus and near the company’s guidance midpoint, alongside adjusted EBITDA that remains essentially in line with market forecasts, underscoring confidence in the long‑term earnings profile.

At the same time, he is fine‑tuning near‑term assumptions—such as slightly lowering second‑quarter same‑store discharge growth—to better mirror management’s recent commentary without materially altering revenue or EBITDA outlooks. Minor changes to the timing of 2026 operating expenses also leave full‑year targets largely intact, indicating that short‑term operational adjustments do not detract from his positive view of Encompass Health’s overall trajectory and support maintaining a Buy recommendation.

Haase covers the Healthcare sector, focusing on stocks such as Encompass Health, Aveanna Healthcare Holdings, and US Physical Therapy. According to TipRanks, Haase has an average return of 22.9% and an 87.50% success rate on recommended stocks.

In another report released on July 9, Barclays also maintained a Buy rating on the stock with a $140.00 price target.

### Related Stocks

- [EHC.US](https://longbridge.com/en/quote/EHC.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [AVAH.US](https://longbridge.com/en/quote/AVAH.US.md)
- [USPH.US](https://longbridge.com/en/quote/USPH.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Encompass Health raises 2026 adjusted EPS outlook to $6.02-$6.25](https://longbridge.com/en/news/295020857.md)
- [Encompass Health (EHC) Projected to Post Quarterly Earnings on Wednesday](https://longbridge.com/en/news/294186112.md)
- [Encompass Health Q2 revenue rises, adjusted EPS beats estimates](https://longbridge.com/en/news/295012254.md)
- [adidas AG Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next](https://longbridge.com/en/news/294598138.md)
- [Prysmian S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models](https://longbridge.com/en/news/294598146.md)